Key result
Forskolin significantly potentiated the positive inotropic effect of milrinone (p < 0.005), but did not potentiate the effects of levosimendan or its active metabolites OR-1855 and OR-1896.
Why the study?
The mechanisms of action of the active levosimendan metabolites OR-1855 and OR-1896 were not fully understood, specifically whether their inotropic effects follow the pattern of levosimendan when combined with forskolin.
Does forskolin potentiate the positive inotropic effect of levosimendan metabolites OR-1855 and OR-1896 in guinea-pig papillary muscle?
Does forskolin potentiate the positive inotropic effect of levosimendan metabolites OR-1855 and OR-1896 in guinea-pig papillary muscle?
The positive inotropic effects of levosimendan and its active metabolites are not potentiated by adenylate cyclase activation, unlike milrinone, suggesting their primary mechanism is calcium sensitization rather than PDE inhibition.
Supports calcium sensitization over PDE inhibition for levosimendan metabolites in vitro; leaves open human translation.
OR-1855 and OR-1896 are 2 hemodynamically active metabolites of the inodilator levosimendan, with calcium sensitizing activity, but their mechanism of action is still not fully understood. It has been previously reported that the positive inotropic effect of levosimendan is not potentiated by the adenylate cyclase activator forskolin, whereas forskolin does potentiate the effects of the phosphodiesterase (PDE) inhibitor milrinone. To ascertain whether the active metabolites follow the same pattern of levosimendan, the positive inotropic effects of OR- 1855 and OR-1896 were studied in guinea-pig-isolated papillary muscle in the presence and absence of forskolin. OR-1855 and OR-1896 were also tested as inhibitors of PDE-III and PDE-IV. Our results show that 0.1 µM forskolin did not potentiate the positive inotropic effect of OR-1855 or OR-1896, as in the case of the parent compound levosimendan. As in previous studies, the positive inotropic effect of milrinone was markedly potentiated in the presence of forskolin. From these data, we propose an explanation for the divergent behavior of the calcium sensitizing drugs and PDE inhibitors.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied Healthy (ex vivo papillary muscle). Forskolin vs. Absence of forskolin was evaluated on Maximum increase in contraction force from baseline for milrinone (p=<0.005). Forskolin significantly potentiated the positive inotropic effect of milrinone (p < 0.005), but did not potentiate the effects of levosimendan or its active metabolites OR-1855 and OR-1896.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: